Approvals & regulatory · first seen yesterday, updated yesterday

FDA clears IND for Systimmune’s bispecific antibody SI-B037

1 outlet FDA

Systimmune Inc. has obtained IND clearance from the FDA for SI-B037, a bispecific antibody targeting immunosuppression and other synergistic mechanisms.

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

BioWorld Articles yesterday
FDA clears IND for Systimmune’s bispecific antibody SI-B037